The present invention relates to a method for designing an efficient chromatographic separation process for a multicomponent mixture, such as a mixture of rare earth elements (REE), a production mixture from a pharmaceutical manufacturing or biotechnology production process, employing the concept of constant pattern mass transfer zone length (L.sub.MTZ,CP) in a non-ideal system having significant spreading of the concentration waves. This present invention can be used for ligand-assisted displacement chromatographic (LAD) as well as conventional displacement chromatographic separation processes. Since this method uses dimensionless groups, it can be used for the design of various scales of separation. This method may also find applications in a continuous process as a multi-zone LAD process using multiple columns.

An ion exchange resin bag 5 includes a bag body 51 and a reinforcing body 52. The bag body 51 has a bottom surface portion 511 that is provided at an end portion opposite to an end portion where an opening is provided and forms a bottom surface of the bag body, and a side surface portion 512 that is connected to the bottom surface portion 511 and forms a side surface of the bag body 51. The reinforcing body 52 has a first reinforcing portion 521 that is fixed to a boundary portion of the bottom surface portion 511 and the side surface portion 512, and a second reinforcing portion 522 that is connected to the first reinforcing portion 521 and fixed to at least a part of the side surface portion 512 and extends from the first reinforcing portion 521 toward the opening.

Methods of preparing steviol glycosides, including Rebaudioside D, Rebaudioside E, Rebaudioside M, Rebaudioside N and Rebaudioside O are provided herein. Sweetener and sweetened consumables containing Rebaudioside D, Rebaudioside E, Rebaudioside M, Rebaudioside N and Rebaudioside O are also provided herein.

Described is a chromatographic column assembly that includes an outer tube comprising a metal, a first conduit disposed within the outer tube, a second conduit disposed within the outer tube, and a first joint located between the first conduit and the second conduit. The outer tube is deformed by a first uniform radial crimp at a longitudinal location along the outer tube that surrounds the first conduit on a first side of the first joint, and a second uniform radial cramp at a longitudinal location along the outer tube that surrounds the second conduit on a second side of the first joint. The first and second uniform radial cramps form a fluid-tight seal between the first conduit and the second conduit and each have a substantially flat base region over which a diameter of the outer tube is reduced for a non-zero longitudinal length.

Provided herein are integrated continuous biomanufacturing processes for producing a therapeutic protein drug substance. Also provided are systems that are capable of continuously producing a therapeutic protein drug substance.

Presented herein is a ligand-assisted elution chromatography process for the separation of metal ions using a sorbent. In particular, the present invention discloses a process of two sets of column system in combination with two sets of eluting ligand solutions to prepare substantially pure rare earth elements, wherein the first set of column comprises strong acid cation exchange resins and the second set of chromatographic columns comprises hydrous polyvalent metal oxide selected from the group consisting of TiO.sub.2, ZrO.sub.2, or SnO.sub.2 and wherein ligand of said second ligand solution coordinates with said hydrous polyvalent metal oxide.

The present invention pertains to methods for manufacturing high titer antibody products. In particular, the invention pertains, in part, to improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Additionally, the present invention further pertains to chromatographic procedures employed to successfully isolate the antibody product subject of the present disclosure.

In certain embodiments, the invention provides a method of purifying a protein of interest from a mixture which comprises the protein of interest and one or more contaminants.

Disclosed is a method for preparing a composition comprising factor VIII (FVIII) and von Willebrand factor (vWF), wherein the content of the von Willebrand factor (vWF) can be controlled by mixing the factor VIII (FVIII) with the von Willebrand factor (vWF) at an appropriate ratio after separately purifying the factor VIII (FVIII) and the von Willebrand factor (vWF) from plasma in a single process. The method can prepare and purify a composition comprising factor VIII (FVIII) and a varying content of von Willebrand factor (vWF) without increasing the amount of impurities other than the von Willebrand factor (vWF) compared to a method of purifying factor VIII (FVIII) separately, without significantly increasing the processing time (within 3 hours) compared to a method of purifying factor VIII (FVIII), and without changing the yield of factor VIII (FVIII).

A compact flow kit for the continuous purification of serums containing therapeutic proteins, manufactured to minimize the risk of leakage or contamination from flexible tubing attachments.